A new Swedish company, Galecto Biotech AB, has received venture funding to develop small-molecule modulators of the galectin family of proteins that could potentially treat fibrosis, inflammation and other diseases. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
